Greenleaf Trust Has $6.37 Billion Position in Stryker Corporation (NYSE:SYK)

Greenleaf Trust cut its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,116,802 shares of the medical technology company's stock after selling 628,360 shares during the quarter. Stryker accounts for about 58.1% of Greenleaf Trust's portfolio, making the stock its largest holding. Greenleaf Trust owned about 4.48% of Stryker worth $6,371,730,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of SYK. Capital A Wealth Management LLC purchased a new position in Stryker during the 4th quarter worth approximately $26,000. Rakuten Securities Inc. grew its position in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares during the period. Goodman Advisory Group LLC acquired a new stake in Stryker during the first quarter valued at $32,000. City Holding Co. grew its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the period. Finally, VSM Wealth Advisory LLC acquired a new stake in Stryker during the fourth quarter valued at $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of Stryker stock traded up $3.64 during trading on Thursday, hitting $395.69. 286,161 shares of the stock were exchanged, compared to its average volume of 1,346,659. The stock's fifty day moving average is $384.17 and its 200 day moving average is $376.78. The stock has a market cap of $151.03 billion, a PE ratio of 53.47, a P/E/G ratio of 2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. Stryker's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.50 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. Stryker's dividend payout ratio is presently 45.41%.

Analyst Upgrades and Downgrades

Several analysts recently commented on SYK shares. Needham & Company LLC restated a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Roth Mkm lifted their target price on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Evercore ISI boosted their price target on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday. JMP Securities reiterated a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Finally, Citigroup restated a "buy" rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $428.55.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.